A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
for Chronic Obstructive Pulmonary Disease (COPD)
67 locations incl. Foley
Sponsor: AstraZeneca
Sex: All·Age: 40 - 80
Code: NCT06883305·Phase 3·Recruiting